

# Yuan-Kai Shi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6551898/publications.pdf>

Version: 2024-02-01

51  
papers

4,880  
citations

279798

23  
h-index

182427

51  
g-index

52  
all docs

52  
docs citations

52  
times ranked

5710  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). <i>Journal of Thoracic Oncology</i> , 2014, 9, 154-162.	1.1	1,131
2	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589.	10.7	950
3	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology</i> , The, 2013, 14, 953-961.	10.7	389
4	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.	7.1	388
5	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	1.1	260
6	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	17.0	226
7	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	6.4	192
8	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e12-e19.	4.6	176
9	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	17.0	155
10	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	1.1	146
11	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000219.	4.5	87
12	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 829-839.	10.7	66
13	Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 152-161.	2.2	66
14	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1015-1026.	1.1	58
15	Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). <i>Cancer</i> , 2015, 121, 3165-3181.	4.1	47
16	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020, 130, 182-192.	2.8	46
17	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12.	17.0	40
18	Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1663-1669.	1.1	37

#	ARTICLE	IF	CITATIONS
19	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) <i>TJ ETQq1</i> 1,0.784314, 348BT /Ove	1.1	31
20	Clinical response to apatinib monotherapy in advanced nonâ€small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 264-269.	1.1	31
21	Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. <i>Clinical Cancer Research</i> , 2020, 26, 6445-6452.	7.0	30
22	Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2019, 24, e1251-e1261.	3.7	29
23	Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. <i>Theranostics</i> , 2020, 10, 6399-6410.	10.0	26
24	High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis. <i>International Journal of Hematology</i> , 2014, 99, 69-78.	1.6	21
25	A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy. <i>Oncologist</i> , 2020, 25, e833-e842.	3.7	19
26	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 38.	17.0	18
27	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as firstâ€line treatment for Chinese patients with unresectable, metastatic, or recurrent nonâ€squamous nonâ€smallâ€cell lung cancer: A multicenter, randomized, doubleâ€blinded, phase III trial. <i>Cancer Communications</i> , 2021, 41, 889-903.	9.2	16
28	Efficacy and safety of rhâ€endostatin (Endostar) combined with pemetrexed/cisplatin followed by rhâ€endostatin plus pemetrexed maintenance in nonâ€small cell lung cancer: A retrospective comparison with standard chemotherapy. <i>Thoracic Cancer</i> , 2018, 9, 1354-1360.	1.9	14
29	The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 11, 100151.	2.9	13
30	Molecular profiling of Chinese <sc>Râ€CHOP</sc> treated <sc>DLBCL</sc> patients: Identifying a highâ€risk subgroup. <i>International Journal of Cancer</i> , 2020, 147, 2611-2620.	5.1	12
31	Circulating tumor cells (<sc>CTCs</sc>)/circulating tumor endothelial cells (<sc>CTECs</sc>) and their subtypes in small cell lung cancer: Predictors for response and prognosis. <i>Thoracic Cancer</i> , 2021, 12, 2749-2757.	1.9	12
32	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged nonâ€small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020, 150, 240-246.	2.0	10
33	Efficacy and safety of aflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9602-9602.	1.6	10
34	Râ€CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large Bâ€cell lymphoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 385-391.	1.1	9
35	The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005â€2020): A systematic review. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 8, 100097.	2.9	9
36	The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 997-1005.	1.9	9

#	ARTICLE	IF	CITATIONS
37	A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, , .	1.1	8
38	<p></p>Characteristics and Management of <em></em>TP53</em>-Mutated Diffuse Large B-Cell Lymphoma Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11515-11522.	1.9	8
39	<p></p>Icotinib as Adjuvant Treatment for Stage II-III A Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4633-4643.	1.9	8
40	Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens. <i>Journal of Cancer</i> , 2020, 11, 1516-1524.	2.5	8
41	Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. <i>Oncotarget</i> , 2016, 7, 72219-72228.	1.8	8
42	High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes. <i>Cancer Science</i> , 2022, 113, 770-783.	3.9	6
43	Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. <i>Investigational New Drugs</i> , 2022, 40, 831-840.	2.6	6
44	Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. <i>Oncology Research</i> , 2020, 28, 127-133.	1.5	5
45	Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 582567.	2.8	5
46	Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2847-2857.	1.8	3
47	Meta-analysis of the prognostic and clinical value of serum 25-hydroxyvitamin D levels in previously untreated lymphoma. <i>Future Oncology</i> , 2021, 17, 1825-1838.	2.4	3
48	Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3119-3129.	1.3	3
49	Treatment strategy, overall survival and associated risk factors among patients with unresectable stage III B/IV non-small cell lung cancer in China (2015-2017): A multicentre prospective study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 23, 100452.	2.9	3
50	Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphoma. <i>Future Oncology</i> , 2022, 18, 1817-1827.	2.4	2
51	A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	1.1	0